DSM-Firmenich stock: Kepler Cheuvreux sets EUR 100.00 target for DSM-Firmenich stock

Published on 10/22/2026 at 18:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 4.66 billion with 5.00 percent like-for-like growth. DSM-Firmenich stock costs EUR 108.80 on October 22, 2026.

Analyst target and reporting date

Kepler Cheuvreux set a EUR 100.00 target on October 6, 2026.
First-half revenue reached EUR 4.66 billion with 5.00 percent like-for-like growth.
DSM-Firmenich stock cost EUR 108.80 at Lang & Schwarz on October 22, 2026 at 6:10 p.m. CEST.
Third-quarter sales are scheduled for November 4, 2026.

Isometrische 3D-Grafik der Wertschöpfungskette von Rohstoff bis Vertrieb — dsm-firmenich AG (ISIN CH1216478797) veranschaulicht ihre Wertschöpfungskette von Rohstoffen bis Vertrieb als isometrische 3D-Grafik, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) received a EUR 100.00 price target from Kepler Cheuvreux on October 6, 2026, alongside a Hold recommendation, according to Ideal Investisseur. At Lang & Schwarz, the stock was trading at EUR 108.80 on October 22, 2026 at 6:10 p.m. CEST.

First-half growth stayed visible

DSM-Firmenich reported EUR 4.66 billion in revenue from continuing operations for the first half of 2026. Like-for-like revenue growth reached 5.00 percent, while second-quarter comparable growth accelerated to 6.00 percent, according to DeBelegger. Adjusted EBITDA came to EUR 900.00 million, compared with EUR 906.00 million a year earlier, while the adjusted margin was 19.30 percent.

Stock stays near its yearly high

The EUR 108.80 Lang & Schwarz price sits EUR 1.05 below the 52-week high of EUR 109.85 and EUR 53.58 above the low of EUR 55.22, both as of October 22, 2026. The latest quote therefore places the stock near the upper end of its annual trading range. The 52-week span is wide, reflecting a substantial change in valuation during the period.

Target and next reporting date

Kepler Cheuvreux's EUR 100.00 target is EUR 8.80 below the Lang & Schwarz price. The distance from the price to the target is 8.80 percent, calculated in euros from EUR 108.80 and EUR 100.00. A separate consensus page lists a median target of EUR 100.00 across four opinions, with one positive and three neutral ratings, according to Ideal Investisseur.

The next scheduled corporate date is November 4, 2026, when DSM-Firmenich is due to publish third-quarter sales, according to Ideal Investisseur. The calendar also lists the fiscal 2026 annual results for February 18, 2027.

Comparison with peers

DSM-Firmenich: P/E minus 22.57, market capitalization EUR 26.6 billion.

BASF (Xetra, EUR): minus 0.40 percent, P/E 7.88, market capitalization EUR 45.2 billion.

Givaudan (SIX, CHF): plus 0.33 percent, P/E 29.51, market capitalization CHF 36.7 billion.

Stock remains below the target

The analyst target and the November reporting date give investors two concrete reference points. The operating figures show 5.00 percent like-for-like growth in the first half of 2026, but adjusted EBITDA fell from EUR 906.00 million to EUR 900.00 million over the same comparison period.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.